Syntonix Pharmaceuticals, Inc.

Bioverativ Therapeutics Inc.

Merrell Dow Pharmaceuticals

Merrell Pharmaceuticals, Inc.

Aventis Pharmaceuticals Inc.

Dyax Corporation

Biogen Idec Hemophilia Inc.

Hoechst Marion Roussel

Biogen Hemophilia Inc.

Other

Aventis Pharma Limited

Alan J Bitonti

Robert T Peters

Susan C Low

Jennifer A Dumont

Daniel S Rivera

Adam Robert Mezo

Haiyan Jiang

Glenn Pierce

Jurg Sommer

Alvin Luk

Lian Li

Karen Nugent

Matt Ottmer

Byron McKinney

Robert Charles Ladner

Norton P Peet

Aaron Sato

Donald Paul Matthews

Michael L Edwards

Clive R Wood

Kevin McDonnell

David R Borcherding

Christopher TenHoor

Albert Sjoerdsma

Arumugam Muruganandam

Patrick Shum

Peter P McCann

Liming Liu

James Stattel

H Randall Munson, Jr

Malini Viswanathan

Jules Freedman

David M Stemerick

Paul S Wright

Donald A Kaplan

William A Van Sickle

Russell J Baumann

James McGivney

H Randall Munson

Francesco Gerald Salituro

James R McCarthy

Jeffrey Paul Whitten

Scott L Harbeson

Ian A McDonald

Philippe Bey

Joe Salas

Esa T Jarvi

Adam R Mezo

Clive Wood

Kevin Mcdonnell

Jurg M Sommer

James M Stattel

Byron Mckinney

Christopher Tenhoor

Patrich Wk Shum

Patrick Wk Shum

Russel J Baumann

Ian A Mcdonald

James R Mccarthy

Peter P Mccann

The present invention provides methods of administering Factor VIII (processed FVIII, single chain FVIII, or a combination thereof); methods of administering chimeric and hybrid polypeptides comprising Factor VIII; chimeric and hybrid polypeptides comprising Factor VIII; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.

Factor VIII chimeric and hybrid polypeptides, and methods of use thereof

The invention relates to a chimeric monomer-dimer hybrid protein wherein the protein comprises a first and a second polypeptide chain, the first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and the second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.

Immunoglobulin chimeric monomer-dimer hybrids

The present invention provides methods of administering Factor VIII; methods of administering chimeric and hybrid polypeptides comprising Factor VIII; chimeric and hybrid polypeptides comprising Factor VIII; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.

Factor VIII-FC chimeric and hybrid polypeptides, and methods of use thereof

Chimeric clotting factors which localize the therapeutic to sites of coagulation (e.g., by being targeted to platelets or being activatable at sites of coagulation), have reduced clearance rates, have improved manufacturability, have reduced thrombogenicity, have enhanced activity, or have more than one of these characteristics are described as are methods for making chimeric clotting factors and methods for improving hemostasis using these clotting factors.

Chimeric clotting factors

The present invention provides cell lines for producing single chain FVIII polypeptides, e.g., chimeric single chain FVIII polypeptides, methods of producing single chain FVIII polypeptides, single chain FVIII polypeptides, and methods of treating Hemophilia A with a single chain Factor VIII polypeptide.

Cell line expressing single chain factor VIII polypeptides and uses thereof

This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.

Antibodies to FeRn and uses thereof

Factor VIII-Fc chimeric and hybrid polypeptides, and methods of use thereof

The invention relates to a chimeric protein comprising at least one clotting factor and at least a portion of an immunoglobulin constant region. The invention relates to a method of treating a hemostatic disorder comprising administering a therapeutically effective amount of a chimeric protein wherein the chimeric protein comprises at least one clotting factor and at least a portion of an immunoglobulin constant region.

Clotting factor-Fc chimeric proteins to treat hemophilia

Fc receptor binding proteins

Clotting factor-fc chimeric proteins to treat hemophilia

Growing community of inventors

Acton, MA, United States of America

Alan J Bitonti